CF PHARMTECH (SEHK: 02652) shares climbed more than 5% in trading. At the time of writing, the stock was up 5.55% to HK$21.3, with a turnover of HK$5.66 million.

The recent price movement follows company announcements. CF PHARMTECH recently disclosed that its Investigational New Drug (IND) application for ICF004, an inhaled dry powder classified as a Class I new drug, has been approved by China's National Medical Products Administration (NMPA).

This product is intended for the treatment of interstitial lung diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The IND approval marks a significant strategic milestone for the company, representing the entry of its inhaled innovative drug candidate into the clinical development phase.

Featuring a potentially first-in-class mechanism of action, the product utilizes an inhaled dry powder delivery route designed to transport the medication directly to the affected areas of the lungs. Preclinical studies for the product have demonstrated a differentiated distribution between lung tissue exposure and systemic blood exposure following inhalation administration, along with observed anti-fibrotic activity and a favorable safety profile in preclinical models.

These research findings provide support for a development strategy focused on enhancing target organ exposure while minimizing systemic exposure through localized, targeted drug delivery. It is important to note, however, that these preclinical results are preliminary. Their translation into safety and efficacy in humans remains to be validated in subsequent clinical trials.